Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated <i>MGMT</i> promoterMichael Lim, Antonio Omuro, Kevin Petrecca et al.|Neuro-Oncology|2022Cited by 508
Detection, Characterization, and Inhibition of FGFR–TACC Fusions in IDH Wild-type GliomaAnna Luisa Di Stefano, Antonio Iavarone, Alessandra Fucci et al.|Clinical Cancer Research|2015Cited by 285
Clinical Spectrum of Encephalitis Associated With Antibodies Against the α-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid ReceptorBastien Joubert, Jérôme Honnorat, Philippe Kerschen et al.|JAMA Neurology|2015Cited by 156
CTIM-25. A RANDOMIZED PHASE 3 STUDY OF NIVOLUMAB OR PLACEBO COMBINED WITH RADIOTHERAPY PLUS TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA WITH METHYLATED MGMT PROMOTER: CHECKMATE 548Michael Weller, Antonio Omuro, Michael Lim et al.|Neuro-Oncology|2021Cited by 29
Clinical value of chromosome arms 19q and 11p losses in low-grade gliomasAgustí Alentorn, Ahmed Idbaïh|Neuro-Oncology|2013Cited by 15